Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261513 | 1.00 | TSHR (0.39) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL3540268 | 0.78 | ALDH1A1 (0.44) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL6662085 | 0.78 | ALDH1A1 (0.44) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL21252166 | 0.77 | TSHR (0.42) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL20331989 | 0.77 | TSHR (0.42) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL21386681 | 0.73 | L3MBTL1 (0.48) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL30619211 | 0.72 | ALDH1A1 (0.42) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL26611531 | 0.72 | ALDH1A1 (0.42) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL31513601 | 0.71 | CYP1A2 (0.45) | TSHRCYP1A2ALDH1A1DDB1CRBN | |
| SCHEMBL31267427 | 0.70 | NSD2 (0.42) | TSHRCYP1A2ALDH1A1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-106349217-B | Serine/threonine kinase inhibitors | 阵列生物制药公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3321262-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2820009-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9708290-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160122316-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-9259470-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140249127-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-8697715-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130252934-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122316-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | TSHR 3732/4885CYP1A2 4352/4885ALDH1A1 3280/4885 |
| US-20140249127-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | TSHR 3732/4885CYP1A2 4352/4885ALDH1A1 3280/4885 |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | TSHR 3732/4885CYP1A2 4352/4885ALDH1A1 3280/4885 |
| US-20130252934-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | TSHR 3732/4885CYP1A2 4352/4885ALDH1A1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.